MNTA  Momenta Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.16 (-1.46%)

Stability Price

Overvalued by 97.18%

Company Metrics

  • 13.83 P/E
  • 12.87 P/S
  • 2.81 P/B
  • -2.193 EPS
  • -146.29% Cash ROIC
  • 11.20 Cash Ratio
  • 0.00 / N/A % Dividend
  • 598,553.00 Avg. Vol.
  • 555.6M Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Momenta Pharmaceuticals Done In by Delay
Barron's - Jan 26, 2015
Momenta Pharmaceuticals ( MNTA MNTA 2.5328330206378986% Momenta Pharmaceuticals Inc. U.S.: Nasdaq USD10.93 0.27 2.5328330206378986% /Date(1422568800195-0600)/ Volume (Delayed 15m) : 461658 AFTER HOURS USD10.93 % Volume ...
First Call Rating Update on Momenta Pharmaceuticals, Inc. - Stafford Daily
Stocks Underperform for the Week: Momenta Pharmaceuticals Inc , Credit ... - Ashburn Daily
Momenta Pharmaceuticals Inc. Files SEC Form SC 13G, Statement of ...
Insurance News Net - Jan 29, 2015
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a U.S.
Momenta Pharmaceuticals, Inc. Pushes Forward
Motley Fool - Nov 5, 2014
At this point, earnings calls for Momenta Pharmaceuticals (NASDAQ: MNTA ) are more an opportunity to update investors than to report revenue and earnings.
Momenta Pharmaceuticals Reports Third Quarter 2014 Financial Results - MarketWatch
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2014 Results ... - Seeking Alpha (registration)
Momenta Pharmaceuticals Inc. Stock Downgraded (MNTA) - Mar 4, 2014
This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, MOMENTA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the ...
Momenta Pharmaceuticals, Inc. Discloses Insider Trading
Stafford Daily - Jan 6, 2015
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA),The President, Biosimilars Busines of Momenta Pharmaceuticals Inc, Franken Michael sold 2,047 shares at $12.29 on December 11, 2014. The Insider selling transaction had a total value worth of $25,158.
SEC Update on Insider Trading Activity: Monmouth R.E. Inv. Corp. , Momenta ... - Wall Street Pulse
Update: Momenta Pharmaceuticals, Inc. Short Interest Disclosure
Bar and Graph Report - 19 hours ago
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), A sharp reduction of 296,076 shares or 4.2% was observed in the short interest of Momenta Pharmaceuticals, Inc. The interest on January 15,2015 came in at 6,789,382 shares and as per the average daily ...
Friday Stocks to Watch: Momenta Pharmaceuticals Inc , Eagle Bulk Shipping Inc ... - Ashburn Daily
Maxim Group Rating Disclosure on Momenta Pharmaceuticals, Inc. - Winston View
Short Interest of Momenta Pharmaceuticals, Inc. Drops by 3.5%
Stafford Daily - Jan 20, 2015
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), A sharp reduction of 257,048 shares or 3.5% was observed in the short interest of Momenta Pharmaceuticals, Inc. The interest on December 31,2014 came in at 7,085,458 shares and as per the average daily ...
Analyst Downgrades: DreamWorks Animation SKG, Inc., Exxon Mobil ...
Schaeffers Research (blog) - Jan 23, 2015
Analysts are weighing in today on entertainment issue Dreamworks Animation Skg Inc (NASDAQ:DWA), commodity concern Exxon Mobil Corporation (NYSE:XOM), and generic drugmaker Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Here's a quick ...
Momenta Pharmaceuticals, Inc. Analyst Rating Update
Stafford Daily - Jan 13, 2015
As many as 3 brokerage firms have rated Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) at 1. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of Neutral.
Momenta Pharmaceuticals Announces Supreme Court Decision to Remand ...
GlobeNewswire (press release) - Jan 21, 2015
CAMBRIDGE, Mass., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the United States Supreme Court has vacated the 2013 decision of the Court of Appeals for the Federal Circuit ("CAFC") which ...
Supreme Court rules for Teva over MS drug patent - Reuters
With local impact on both sides, Supreme Court sides with Teva in drug dispute - (blog)